Welcome back to another edition of Endpoints Weekly! We hope you all have been staying safe indoors as the Canadian wildfires blanketed much of the US Northeast this week. Hopefully ...
July 18, 2026 06:00 AM EDT
Weekly
Biogen’s mixed Alzheimer’s data; Two new startups launch; and more
Max Gelman
Nicole DeFeudis
Pharmalittle: We're reading about a Biogen Alzheimer's drug, skyrocketing 340B drug sales, and more
All eyes on data on Biogen's tau therapy
The end for GSK's chronic cough treatment
Predicting biotech clinical trials & a new Alzheimer's drug controversy
Akero team, backed by Fairmount, launches new immunology company
Improvements in Alzheimer's testing could make diagnostics more accessible, informative
Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan…
Welcome back to Endpoints Weekly. The biggest news this week was Marty Makary’s resignation from his role as FDA Commissioner.…
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Welcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will…
